Synta names new corporate development VP
This article was originally published in Scrip
Synta Pharmaceuticals, a biopharmaceutical company developing and commercializing small molecule drugs for conditions including cancer and chronic inflammatory diseases, has named Steven Bernitz senior vice-president of corporate development. Prior to joining the Lexington, Massachusetts-based firm, Mr Bernitz was a general partner and head of the BioPharm practice at Extera Partners, a business development advisory firm.
You may also be interested in...
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.